abrdn plc Buys Shares of 108,480 LivaNova PLC (NASDAQ:LIVN)

abrdn plc purchased a new position in LivaNova PLC (NASDAQ:LIVN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 108,480 shares of the company's stock, valued at approximately $5,613,000. abrdn plc owned about 0.20% of LivaNova at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of LIVN. SG Americas Securities LLC purchased a new position in shares of LivaNova in the 3rd quarter worth about $1,672,000. Exchange Traded Concepts LLC bought a new stake in LivaNova in the 3rd quarter worth about $555,000. Handelsbanken Fonder AB increased its holdings in LivaNova by 100.0% in the 3rd quarter. Handelsbanken Fonder AB now owns 17,474 shares of the company's stock worth $924,000 after buying an additional 8,737 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in LivaNova by 20.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,176 shares of the company's stock worth $591,000 after buying an additional 1,923 shares in the last quarter. Finally, Strs Ohio increased its holdings in LivaNova by 560.0% in the 3rd quarter. Strs Ohio now owns 9,900 shares of the company's stock worth $523,000 after buying an additional 8,400 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on LIVN shares. Robert W. Baird lifted their price objective on LivaNova from $56.00 to $62.00 and gave the stock a "neutral" rating in a report on Thursday, February 22nd. StockNews.com upgraded LivaNova from a "hold" rating to a "buy" rating in a research note on Thursday. Barclays boosted their price target on LivaNova from $57.00 to $61.00 and gave the company an "equal weight" rating in a research note on Monday, February 26th. Mizuho restated a "buy" rating and set a $75.00 price target on shares of LivaNova in a research note on Wednesday, March 27th. Finally, Needham & Company LLC restated a "buy" rating and set a $72.00 price target on shares of LivaNova in a research note on Wednesday, March 20th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $64.40.

LivaNova Price Performance

NASDAQ LIVN traded up $0.43 during trading hours on Friday, reaching $55.53. The company's stock had a trading volume of 553,327 shares, compared to its average volume of 554,401. The firm's 50-day moving average price is $54.13 and its 200-day moving average price is $50.66. The company has a quick ratio of 2.51, a current ratio of 2.95 and a debt-to-equity ratio of 0.44. LivaNova PLC has a 1 year low of $42.75 and a 1 year high of $59.86. The company has a market capitalization of $3.00 billion, a price-to-earnings ratio of 173.54 and a beta of 0.89.

LivaNova (NASDAQ:LIVN - Get Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The company reported $0.87 EPS for the quarter, topping analysts' consensus estimates of $0.77 by $0.10. LivaNova had a return on equity of 12.23% and a net margin of 1.53%. The company had revenue of $310.10 million for the quarter, compared to analysts' expectations of $287.65 million. During the same period in the previous year, the firm earned $0.81 EPS. The firm's revenue was up 12.8% compared to the same quarter last year. On average, equities research analysts predict that LivaNova PLC will post 3.01 EPS for the current fiscal year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.